Donafenib

Donafenib, sold under the brand name Zepsun, is a pharmaceutical drug for the treatment of cancer.

Trade namesZepsun

Other namesCM-4307

Legal status

• Rx in China

CAS Number

• 1130115-44-4

Quick facts Clinical data, Trade names ...

Donafenib

Clinical data
Trade names	Zepsun
Other names	CM-4307
Legal status
Legal status	Rx in China
Identifiers
IUPAC name 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-(trideuteriomethyl)pyridine-2-carboxamide
CAS Number	1130115-44-4
PubChem CID	25191001
DrugBank	DB15414
ChemSpider	23937167
UNII	41XGO0VS1U
ChEMBL	ChEMBL4297490
CompTox Dashboard (EPA)	DTXSID90648995
Chemical and physical data
Formula	C21H16ClD3F3N4O3
Molar mass	470.87 g·mol−1
3D model (JSmol)	Interactive image
SMILES [2H]C([2H])([2H])NC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
InChI InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)/i1D3 Key:MLDQJTXFUGDVEO-FIBGUPNXSA-N

Close

In China, donafenib is approved for the treatment of unresectable hepatocellular carcinoma in patients who have not previously received systemic treatment.^[1][2]

Donafenib is a kinase inhibitor that targets Raf kinase and various receptor tyrosine kinases.^[3] It is a deuterated derivative of sorafenib with improved pharmacokinetic properties.^[4][5]